These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Clinical outcomes according to permanent discontinuation of clopidogrel or placebo in the CHARISMA trial. Collet JP, Montalescot G, Steg PG, Steinhubl SR, Fox KA, Hu TF, Johnston SC, Hamm CW, Bhatt DL, Topol EJ. Arch Cardiovasc Dis; 2009; 102(6-7):485-96. PubMed ID: 19664568 [Abstract] [Full Text] [Related]
6. Non-cardiac surgery in patients with coronary stents: the RECO study. Albaladejo P, Marret E, Samama CM, Collet JP, Abhay K, Loutrel O, Charbonneau H, Jaber S, Thoret S, Bosson JL, Piriou V. Heart; 2011 Oct; 97(19):1566-72. PubMed ID: 21791513 [Abstract] [Full Text] [Related]
7. Bleeding complications associated with combinations of aspirin, thienopyridine derivatives, and warfarin in elderly patients following acute myocardial infarction. Buresly K, Eisenberg MJ, Zhang X, Pilote L. Arch Intern Med; 2005 Apr 11; 165(7):784-9. PubMed ID: 15824298 [Abstract] [Full Text] [Related]
11. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. Cannon CP, Husted S, Harrington RA, Scirica BM, Emanuelsson H, Peters G, Storey RF, DISPERSE-2 Investigators. J Am Coll Cardiol; 2007 Nov 06; 50(19):1844-51. PubMed ID: 17980250 [Abstract] [Full Text] [Related]
12. The potential role of prasugrel in secondary prevention of ischemic events in patients with acute coronary syndromes. Toth PP. Postgrad Med; 2009 Jan 06; 121(1):59-72. PubMed ID: 19179814 [Abstract] [Full Text] [Related]
13. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. Fox KA, Mehta SR, Peters R, Zhao F, Lakkis N, Gersh BJ, Yusuf S, Clopidogrel in Unstable angina to prevent Recurrent ischemic Events Trial. Circulation; 2004 Sep 07; 110(10):1202-8. PubMed ID: 15313956 [Abstract] [Full Text] [Related]
14. Combining warfarin and antiplatelet therapy after coronary stenting in the Global Registry of Acute Coronary Events: is it safe and effective to use just one antiplatelet agent? Nguyen MC, Lim YL, Walton A, Lefkovits J, Agnelli G, Goodman SG, Budaj A, Gulba DC, Allegrone J, Brieger D, GRACE Investigators. Eur Heart J; 2007 Jul 07; 28(14):1717-22. PubMed ID: 17562671 [Abstract] [Full Text] [Related]
19. Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Berger PB, Bhatt DL, Fuster V, Steg PG, Fox KA, Shao M, Brennan DM, Hacke W, Montalescot G, Steinhubl SR, Topol EJ, CHARISMA Investigators. Circulation; 2010 Jun 15; 121(23):2575-83. PubMed ID: 20516378 [Abstract] [Full Text] [Related]
20. Usefulness of platelet response to clopidogrel by point-of-care testing to predict bleeding outcomes in patients undergoing percutaneous coronary intervention (from the Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty-Bleeding Study). Patti G, Pasceri V, Vizzi V, Ricottini E, Di Sciascio G. Am J Cardiol; 2011 Apr 01; 107(7):995-1000. PubMed ID: 21256470 [Abstract] [Full Text] [Related] Page: [Next] [New Search]